|
JP2006001920A
|
|
Medicinal preparation
|
|
CA2504820A1
|
|
Pyrazolonaphthyridine derivatives
|
|
CA2463395A1
|
|
Therapeutic agents for low hdl-cholesterolemia
|
|
EP1403270A1
|
|
Pde iv inhibitors
|
|
EP1364646A1
|
|
Fenofibrate-containing composition
|
|
WO0187880A1
|
|
1-(benzothiazol-2-yl)pyrazole derivatives and cox-2 inhibitors containing the same
|
|
JP2001286286A
|
|
Hemeoxygenase-1 gene mutant and its use
|
|
EP1236725A1
|
|
Novel 1,8-naphthyridin-2(1h)-one derivatives
|
|
JP2001226328A
|
|
Intermediate of capsiamide and improved method for producing capsiamide
|
|
EP1062952A1
|
|
Bubbling enteric preparations
|
|
JPH10338634A
|
|
Medicinal composition
|
|
WO9846594A1
|
|
Pyrazole derivatives and cox inhibitors containing them
|
|
JPH10226678A
|
|
Separation of optical isomer of pentazocine
|
|
JPH11158066A
|
|
Pharmaceutical product containing ibuprofen
|
|
JPH1129476A
|
|
Depressant for drug dependence
|
|
JPH10298074A
|
|
Composition containing vitamins
|
|
JPH10287568A
|
|
Therapeutic agent for dipsomania
|
|
JPH10120644A
|
|
2-ureido-benzamide derivative
|
|
JPH09227364A
|
|
Stable teprenone formulation
|
|
JPH08208631A
|
|
2-substituted benzothiazole derivative and prophylactic and therapeutic agent for diabetes complication containing the same
|
